The options considered, and what survives

Scope was open, so the option set was generated capability-first by an isolated agent working outward from what Innovera demonstrably has, rather than from what the deck already names. It produced 77 candidates from 18 capability entries: 22 carried, 24 marginal, 31 rejected. The full set, including everything rejected, is retained with the reasoning for each.

The 22 carried candidates fall into six groups.

Package and price the existing product differently. Convert pilots to the annual enterprise license; sell portfolio-level allocation; sell a pre-paid pool of initiative slots the client draws down; sell single deliverables at low prices as a land motion; sell the Navigate monitor on its own as an annuity; price on outcomes tied to a gate decision.

Concentrate somewhere. Energy transition, carbon and sustainability, which carries three of the four evidenced engagements. Advanced materials and medical-device commercialization, which carries the flagship case. Japan through the Mitsubishi relationship and an SVP who ran Mitsubishi's Silicon Valley innovation office. Korea through the one converted account.

Point the same capability at an adjacent decision. Capital-project investment decisions, which have the same structure and far more money attached. Enterprise AI portfolio triage, which is the same decision with today's budget attached. Private-equity commercial diligence.

Sell through the people who produce strategy today. Supply the innovation-management and portfolio software incumbents, who own enterprise distribution and have no reasoning layer. White-label to mid-tier consultancies. Sell the Studio as the workspace they run engagements inside.

Monetize the delivery capability directly. A fractional strategy team on subscription. A managed service for a corporate incubation program. A structured expert second opinion on a case the client already wrote. A corporate capability-building program, which the team's existing teaching record supports and which could start next quarter.

Build the data asset. A comparative benchmark subscription across initiatives, and the outside-in research product sold on its own to insights functions.

The rejections worth stating, because the material's story might otherwise suggest them: running the 500-person expert network as an expert network, where the established players operate at a scale orders of magnitude larger and 500 experts is an operational convenience rather than a market position; licensing the framework corpus (the frameworks are public and only the encoding is proprietary, and it does not detach from the product); selling accumulated initiative data (twenty records, and confidentiality on unlaunched strategy is the one thing enterprises will not trade); and a self-serve product for smaller companies (removing the advisor requires the price to fall roughly fiftyfold to reach a buyer who still cannot pay).

The Evaluation Engine is the clearest of the three capabilities that yielded no carried option. It scores analysis quality and blocks weak work from entering the graph, it is architecturally the most distinctive thing in the stack, and every way of selling it separately fails: the buyers who want analysis-quality tooling are engineers buying near a zero price floor, and the buyers who would pay executive prices want the answer rather than the rubric that produced it. It is a feature, not a product.

Three capabilities produced no carried option, and two of those are gaps rather than findings.

The claims graph is the asset this memo ranks first for defensibility, and nothing in the carried set monetizes it. Options that follow directly from it: a decision record sold to boards, internal audit or regulated filers who have to evidence how a capital commitment was reached; a governance artifact attached to the controls positioning already in the company's material; an evidence pack for the capital-project decisions identified above as an adjacent market with more money attached. An asset ranked first for defensibility and yielding nothing is the most likely place a real option was missed.

The credential base appears in this analysis only as a presentation risk. The same 200+ enterprises and 1,000+ executives are a distribution asset: a referral network, a diligence panel, or a route to the exact buyer this memo says is hard to reach without a founder in the room. Treating an asset as a liability in one section and as the main reason deals close in another is inconsistent, and the second reading deserves an option.

The self-analysis itself is the third. The brief's premise is that Innovera evaluates its own business with its own product. That makes this document a worked example of the product applied to a company investors are being asked to fund, which speaks to two gaps named elsewhere here: that the value claim is unsubstantiated, and that no direct competitor comparison exists. It is already produced and costs nothing further.

The pattern across the whole set is the one that matters. The options that pay soonest all monetize the delivery capability, which is strong and evidenced. The options that reach the revenue curve in the deck all require the software to be finished, and the portfolio optimizer is described in Innovera's own speaker notes as the layer being built now. That tension is the strategic content of this case.